Header Logo

Connection

YOCHAI BIRNBAUM to Myocardial Reperfusion Injury

Back to Details
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Myocardial Reperfusion Injury.
YOCHAI BIRNBAUM
Connection Strength
9.441
Myocardial Reperfusion Injury
  1. Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury. Cardiovasc Drugs Ther. 2023 08; 37(4):625-646.
    View in: PubMed
    Score: 0.669
  2. Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat. Cardiovasc Drugs Ther. 2023 04; 37(2):221-224.
    View in: PubMed
    Score: 0.646
  3. Does Inhibition of Nuclear Factor Kappa B Explain the Protective Effect of Ticagrelor on Myocardial Ischemia-Reperfusion Injury? J Cardiovasc Pharmacol. 2020 02; 75(2):108-111.
    View in: PubMed
    Score: 0.580
  4. The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury. Cardiovasc Drugs Ther. 2019 08; 33(4):489-498.
    View in: PubMed
    Score: 0.560
  5. Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016 Dec; 30(6):539-550.
    View in: PubMed
    Score: 0.466
  6. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015 Aug; 35(8):1805-14.
    View in: PubMed
    Score: 0.420
  7. Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings. Cardiovasc Drugs Ther. 2015; 29(5):461-7.
    View in: PubMed
    Score: 0.408
  8. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014 Sep; 34(9):2078-85.
    View in: PubMed
    Score: 0.395
  9. Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury. J Cardiovasc Pharmacol Ther. 2014 Sep; 19(5):417-25.
    View in: PubMed
    Score: 0.385
  10. Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord. 2012 Dec; 10(6):387-90.
    View in: PubMed
    Score: 0.348
  11. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011 Nov; 106(6):925-52.
    View in: PubMed
    Score: 0.324
  12. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 2011 May 01; 43(10):534-42.
    View in: PubMed
    Score: 0.305
  13. Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Ann N Y Acad Sci. 2010 Oct; 1207:76-82.
    View in: PubMed
    Score: 0.304
  14. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H153-64.
    View in: PubMed
    Score: 0.295
  15. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008 Dec; 295(6):H2436-46.
    View in: PubMed
    Score: 0.265
  16. Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat. Cardiovasc Drugs Ther. 2008 Aug; 22(4):275-82.
    View in: PubMed
    Score: 0.254
  17. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H813-8.
    View in: PubMed
    Score: 0.239
  18. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007 Jun; 292(6):H2891-7.
    View in: PubMed
    Score: 0.236
  19. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther. 2006 Feb; 20(1):27-36.
    View in: PubMed
    Score: 0.220
  20. Reperfusion-related polymorphic ventricular tachycardia as a possible mechanism of sudden death in patients with anomalous coronary arteries. Am J Med Sci. 2005 Jun; 329(6):327-9.
    View in: PubMed
    Score: 0.210
  21. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005 Feb 01; 65(2):345-55.
    View in: PubMed
    Score: 0.205
  22. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis. 2004 Feb; 15(1):53-8.
    View in: PubMed
    Score: 0.191
  23. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther. 2003 Jan; 17(1):25-30.
    View in: PubMed
    Score: 0.178
  24. A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovasc Drugs Ther. 2024 Aug; 38(4):775-797.
    View in: PubMed
    Score: 0.173
  25. Circulating blood cells and extracellular vesicles in acute cardioprotection. Cardiovasc Res. 2019 06 01; 115(7):1156-1166.
    View in: PubMed
    Score: 0.138
  26. Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Cell Physiol Biochem. 2019; 53(6):961-981.
    View in: PubMed
    Score: 0.135
  27. Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction? J Cardiovasc Pharmacol Ther. 2019 05; 24(3):215-224.
    View in: PubMed
    Score: 0.134
  28. The effect of CY1503, a sialyl Lewisx analog blocker of the selectin adhesion molecules, on infarct size and "no-reflow" in the rabbit model of acute myocardial infarction/reperfusion. J Mol Cell Cardiol. 1997 Aug; 29(8):2013-25.
    View in: PubMed
    Score: 0.122
  29. Aleglitazar, a Balanced Dual PPARa and -? Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovasc Drugs Ther. 2016 Apr; 30(2):129-41.
    View in: PubMed
    Score: 0.111
  30. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther. 2011 Dec; 25(6):505-15.
    View in: PubMed
    Score: 0.082
  31. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-?-independent manner. Basic Res Cardiol. 2011 May; 106(3):431-46.
    View in: PubMed
    Score: 0.078
  32. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc Drugs Ther. 2010 Dec; 24(5-6):391-9.
    View in: PubMed
    Score: 0.077
  33. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
    View in: PubMed
    Score: 0.073
  34. Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signalling. Cardiovasc Res. 2009 Dec 01; 84(3):452-60.
    View in: PubMed
    Score: 0.070
  35. Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther. 2008 Mar; 13(1):72-9.
    View in: PubMed
    Score: 0.063
  36. Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H376-84.
    View in: PubMed
    Score: 0.059
  37. Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. Am J Physiol Heart Circ Physiol. 2012 May 01; 302(9):H1806-17.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.